Newswise — Abingdon Health Ltd, is pleased to announce that it has gained regulatory approval by the Therapeutic Goods Administration (TGA) in Australia for Seralite®– FLC. Seralite®– FLC is a rapid test for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The features of the Seralite®– FLC device provide informative and empowering benefits to clinicians and laboratory professionals. By obtaining results rapidly rather than days or weeks, clinicians are able to better understand disease status and can make informed decisions quickly and efficiently.
Fiona Kilvington, Head of Sales & Marketing at Abingdon Health, said:“The regulatory approval by TGA allows clinical laboratories in Australia to have access to the Seralite®– FLC product. We believe this important milestone in product availability enables the provision of rapid free light chain results to aid the diagnosis and monitoring of Multiple Myeloma which will not only benefit the patient but also the Australian Health Care system.”
RSS